According
to the study, ‘CARDIAC VALVE
REPAIRS-MEDICAL DEVICES PIPELINE ASSESSMENT, 2018’, for many,
valve tightness can be relieved during a procedure called balloon valvuloplasty
which is done as part of a cardiac catheterization which is less invasive than
general surgery or open heart surgery. Commissurotomy is used for narrowed
valves, where the leaflets are thickened and sometimes stuck together. The
surgeon opens the valve by cutting the points where the leaflets meet. New
progress in medical science has been improving the scenario considerably,
evident by developments in treatment of ailments such as mitral regurgitation.
Today,
there is an immediate concern regarding heart diseases which are on the rise
owing to lifestyle imbalances. There are several heart valve ailments, all of
which reduce the efficiency of the heart by reducing functionality of the
valves. Options are available today that can resolve valve ailments either by
repair or by replacement. When possible it is generally best to repair a valve
and preserve a person’s own tissue in the heart. However, if the tissue is too
damaged, a replacement valve may be used from another human heart, an animal or
a manufactured mechanical valve.
Mitral
regurgitation is the most common valvular disease and significant severity
levels of mitral regurgitation are found in a few people above the age of 65
years. There are several features of the mitral valve for instance, its
saddle-shaped non calcified annulus and irregular leaflet geometry, that make a
transcatheter approach to repair or replace the valve more challenging compared
to the aortic valve. New transcatheter minimally invasive technologies are
being developed to address mitral valve disease in patients deemed too high a
risk for conventional open-heart surgery. Several devices are under
investigation for mitral valve repair, targeting the mitral valve leaflets,
chordae tendinae and mitral annulus. The MitraClip device is the only Food and
Drug Administration (FDA) approved device to treat mitral regurgitation by
targeting the mitral leaflets. Currently there are more than ten different
transcatheter mitral valves that are in various stages of development and
clinical trials. These transcatheter mitral valves can be delivered either
through a transseptal, transapical, transaortic, or left atriotomy approach.
Many
big medical companies are exploring the prospects of cardiac valve treatment. US
based Abbott Laboratories is a healthcare company that has recently been part
of major developments in mitral valve treatment. In May 2018, Abbott announced favorable
outcomes from the first hundred patients treated in a global study of its
Tendyne Transcatheter Mitral Valve Replacement System (TMVR) system, the first
and only mitral replacement valve that is repositionable and fully retrievable
to allow for more precise implantation to improve patient outcome. This trial
is the largest study of a transcatheter mitral valve replacement device to
date.
Cardiac
valve treatment is proving to be a flourishing research sector with more and
more developments taking place. Repairing cardiac valves is increasingly
incorporating new research evident by the developments in treatment of mitral
regurgitation. New devices are being developed and certified by reliable
establishments such as the US based FDA and many more are in the making. Global
giants like Abbott are also showing their interests in heart valve treatment
evident by their recent research project on transcatheter mitral valve
replacement.
To know more, click on the link below:
Related Reports:-
+91-9015378249
